These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 23422771)

  • 1. What causes a prolactinoma to be aggressive or to become a pituitary carcinoma?
    Phillips J; East HE; French SE; Melcescu E; Hamilton RD; Nicholas WC; Fratkin JF; Parent AD; Luzardo G; Koch CA
    Hormones (Athens); 2012; 11(4):477-82. PubMed ID: 23422771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain and optic chiasmal herniation following cabergoline treatment for a giant prolactinoma: wait or intervene?
    Papanastasiou L; Fountoulakis S; Pappa T; Liberopoulos K; Malliopoulos D; Markou A; Piaditis G
    Hormones (Athens); 2014; 13(2):290-5. PubMed ID: 24776630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.
    Murakami M; Mizutani A; Asano S; Katakami H; Ozawa Y; Yamazaki K; Ishida Y; Takano K; Okinaga H; Matsuno A
    Neurosurgery; 2011 Jun; 68(6):E1761-7; discussion E1767. PubMed ID: 21389894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain and optic chiasmal herniations into sella after cabergoline therapy of giant prolactinoma.
    Dhanwal DK; Sharma AK
    Pituitary; 2011 Dec; 14(4):384-7. PubMed ID: 19381817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Falsely low serum prolactin in two cases of invasive macroprolactinoma.
    Schöfl C; Schöfl-Siegert B; Karstens JH; Bremer M; Lenarz T; Cuarezma JS; Samii M; von zur Mühlen A; Brabant G
    Pituitary; 2002; 5(4):261-5. PubMed ID: 14558675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men.
    Shimon I; Benbassat C; Hadani M
    Eur J Endocrinol; 2007 Feb; 156(2):225-31. PubMed ID: 17287412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of a prolactin-secreting pituitary microadenoma into a fatal carcinoma: a case report.
    Guastamacchia E; Triggiani V; Tafaro E; De Tommasi A; De Tommasi C; Luzzi S; Sabbà C; Resta F; Terreni MR; Losa M
    Minerva Endocrinol; 2007 Sep; 32(3):231-6. PubMed ID: 17912159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas.
    Iyer P; Molitch ME
    Endocr Pract; 2011; 17(3):e55-8. PubMed ID: 21324816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Giant prolactinomas in men: efficacy of cabergoline treatment.
    Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
    Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ectopic Cavernous Sinus Microprolactinoma Treated Medically.
    Minns RM; Barranco-Trabi J; Yiu AC; Hussain A; Elegino-Steffens DU
    Mil Med; 2023 May; 188(5-6):1304-1306. PubMed ID: 35758408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Giant prolactinoma presented as unilateral exophthalmos in a prepubertal boy: response to cabergoline.
    Krassas GE; Pontikides N; Kaltsas T
    Horm Res; 1999; 52(1):45-8. PubMed ID: 10640900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Recognition and Initiation of Temozolomide Chemotherapy for Refractory, Invasive Pituitary Macroprolactinoma with Long-Term Sustained Remission.
    Barkhoudarian G; Palejwala SK; Ogunbameru R; Wei H; Eisenberg A; Kelly DF
    World Neurosurg; 2018 Oct; 118():118-124. PubMed ID: 30031177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prolactinoma in a child showing high MIB-1 labeling index: a case report].
    Akamine S; Miyamoto T; Sugiura Y; Takehara S; Hiramatsu H; Nishizawa S; Yokota N
    No Shinkei Geka; 2000 Jun; 28(6):547-53. PubMed ID: 10875113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A giant prolactinoma presenting with unilateral exophthalmos: effect of cabergoline and review of the literature.
    Berwaerts J; Verhelst J; Abs R; Appel B; Mahler C
    J Endocrinol Invest; 2000 Jun; 23(6):393-8. PubMed ID: 10908167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proptosis as the presenting sign of giant prolactinoma in a prepubertal boy: successful resolution of hydrocephalus by use of medical therapy.
    Cackett P; Eunson G; Bath L; Mulvihill A
    Future Oncol; 2012 Dec; 8(12):1621-6. PubMed ID: 23231524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Giant prolactinomas presenting as skull base tumors.
    Minniti G; Jaffrain-Rea ML; Santoro A; Esposito V; Ferrante L; Delfini R; Cantore G
    Surg Neurol; 2002 Feb; 57(2):99-103; discussion 103-4. PubMed ID: 11904200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prolactinoma treatment status in the cabergoline era].
    Watanabe S; Takano S; Akutsu H; Sato H; Matsumura A
    No Shinkei Geka; 2011 Nov; 39(11):1045-54. PubMed ID: 22036815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive giant prolactinoma with loss of therapeutic response to cabergoline: expression of angiogenic markers.
    Mallea-Gil MS; Cristina C; Perez-Millan MI; Villafañe AM; Ballarino C; Stalldecker G; Becu-Villalobos D
    Endocr Pathol; 2009; 20(1):35-40. PubMed ID: 19172414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pituitary apoplexy due to prolactinoma in a Taiwanese boy: patient report and review of the literature.
    Yang MH; Chuang H; Jung SM; Van YH; Lo FS
    J Pediatr Endocrinol Metab; 2003 Dec; 16(9):1301-5. PubMed ID: 14714755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report of sarcoma of the sella caused by postoperative radiotherapy for a prolactin-producing pituitary adenoma.
    Kurosaki M; Kambe A; Ishibashi M; Watanabe T; Horie Y
    Brain Tumor Pathol; 2014 Jul; 31(3):187-91. PubMed ID: 24446079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.